Advertisement

Inclusion Body Myositis

  • Mazen M. DimachkieEmail author
  • Richard J. Barohn
Nerve and Muscle (M Hirano and LH Weimer, Section Editors)
Part of the following topical collections:
  1. Topical Collection on Nerve and Muscle

Abstract

Sporadic inclusion body myositis (IBM) is the most common idiopathic inflammatory myopathy (IIM) after age 50 years. It presents with chronic insidious proximal leg and distal arm asymmetric muscle weakness. Despite similarities with polymyositis (PM), it is likely that IBM is primarily a degenerative disorder rather than inflammatory muscle disease. IBM is associated with a modest degree of creatine kinase (CK) elevation and an electromyogram (EMG) demonstrates a chronic irritative myopathy. Muscle histopathology demonstrates endomysial inflammatory exudates surrounding and invading non-necrotic muscle fibers often times accompanied by rimmed vacuoles. We review IBM with emphasis on recent developments in the field and discuss ongoing clinical trials.

Keywords

Inclusion body myositis Idiopathic inflammatory myopathies Polymyositis Pathology Pathophysiology Treatment Prognosis 

Notes

Disclosure

No potential conflicts of interest relevant to this article were reported.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Phillips BA, Zilko PJ, Mastaglia FL. Prevalence of sporadic inclusion body myositis in Western Australia. Muscle Nerve. 2000;23(6):970–2.PubMedCrossRefGoogle Scholar
  2. 2.
    Lotz BP, Engel AG, Nishino H, Stevens JC, Litch WJ. Inclusion body myositis. Observations in 40 patients. Brain. 1989;112(Pt 3):727–47.PubMedCrossRefGoogle Scholar
  3. 3.
    Badrising UA, Maat-Schieman ML, van Houwelingen JC, et al. Inclusion body myositis. Clinical features and clinical course of the disease in 64 patients. Neurology. 2005;252(12):1448–54.CrossRefGoogle Scholar
  4. 4.
    Wilson FC, Ytterberg SR, St Sauver JL, et al. Epidemiology of sporadic inclusion body myositis and polymyositis in Olmsted County, Minnesota. J Rheumatol. 2008;35(3):445–7.PubMedGoogle Scholar
  5. 5.
    Amato AA, Gronseth GS, Jackson, et al. Inclusion body myositis: clinical and pathological boundaries. Ann Neurol. 1995;40:581–6.CrossRefGoogle Scholar
  6. 6.
    Barohn RJ, Amato AA. Inclusion body myositis. Curr Treat Options Neurol. 2000;2:7–12.PubMedCrossRefGoogle Scholar
  7. 7.
    Badrising UA, Maat-Schieman M, van Duinen SG, et al. Epidemiology of inclusion body myositis in The Netherlands: a nationwide study. Neurology. 2000;55:1385–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Lindberg C, Persson LI, Bjorkander J, Oldfors A. Inclusion body myositis: clinical, morphological, physiological, and laboratory findings in 18 cases. Acta Neurol Scand. 1994;89:123–31.PubMedCrossRefGoogle Scholar
  9. 9.
    Sayers ME, Chou SM, Calabrese LH. Inclusion body myositis: analysis of 32 cases. J Rheumatol. 1992;19:1385–9.PubMedGoogle Scholar
  10. 10.
    Needham M, James I, Corbett A, et al. Sporadic inclusion body myositis: phenotypic variability, and influence of HLA-DR3 in a cohort of 57 Australian cases. J Neurol Neurosurg Psychiatry. 2008;79(9):1056–60.PubMedCrossRefGoogle Scholar
  11. 11.
    Barohn RJ, Amato AA, Sahenk Z, Kissel JT, Mendell JR. Inclusion body myositis: explanation for poor response to immunosuppressive therapy. Neurology. 1995;45(7):1302–4.PubMedCrossRefGoogle Scholar
  12. 12.
    Estephan B, Barohn RJ, Dimachkie MM, et al. Sporadic IBM: a case cohort. J Clin Neuromuscul Dis. 2011;12(3):18–9.Google Scholar
  13. 13.
    •• Griggs RC, Askanas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol. 1995;38(5):705–13. Authors of this article propose diagnostic criteria for definite and possible sporadic inclusion body myositis based on a combination of clinical features and laboratory findings including serum creatine kinase, electromyography, and muscle histopathology. This is the first major effort to define diagnostic criteria for IBM. These criteria have withstood the test of time with some additions as in reference 14.PubMedCrossRefGoogle Scholar
  14. 14.
    •• Hilton-Jones D, Miller A, Parton M, et al. Inclusion body myositis: MRC Centre for Neuromuscular Diseases, IBM workshop, London, 13 June, 2008. Neuromuscul Disord. 2010;20(2):142–7. In addition to the Griggs categories of pathologically defined IBM and possible IBM, participants of the 2008 European Neuromuscular Center workshop introduced clinically defined IBM to include IBM cases with weakness involving finger flexion more than shoulder abduction as well as knee extension more than hip flexion. The pathologic criteria for possible IBM and clinically defined IBM are invasion of non-necrotic fibers by mononuclear cells, or rimmed vacuoles, or increased MHC-1 expression on the surface of muscle fibers. This facilitates the diagnosis of patients who fulfill clinical criteria for IBM but do not have the pathologic features set forth by Griggs et al.PubMedCrossRefGoogle Scholar
  15. 15.
    Amato AA, Barohn RJ. Inclusion body myositis: old and new concepts. J Neurol Neurosurg Psychiatry. 2009;80(11):1186–93.PubMedCrossRefGoogle Scholar
  16. 16.
    Garlepp MJ, Laing B, Zilko PJ, et al. HLA associations with inclusion body myositis. Clin Exp Immunol. 1994;98:40–5.PubMedCrossRefGoogle Scholar
  17. 17.
    Degardin A, Morillon D, Lacour A, Cotten A, Vermersch P, Stojkovic T. Morphologic imaging in muscular dystrophies and inflammatory myopathies. Skeletal Radiol. 2010;39(12):1219–27.PubMedCrossRefGoogle Scholar
  18. 18.
    Cox FM, Reijnierse M, van Rijswijk CS, Wintzen AR, Verschuuren JJ, Badrising UA. Magnetic resonance imaging of skeletal muscles in sporadic inclusion body myositis. Rheumatology. 2011;50(6):1153–61.PubMedCrossRefGoogle Scholar
  19. 19.
    Maetzler W, Reimold M, Schittenhelm J, et al. Increased [11C]PIB-PET levels in inclusion body myositis are indicative of amyloid beta deposition. J Neurol Neurosurg Psychiatry. 2011;82(9):1060–2.PubMedCrossRefGoogle Scholar
  20. 20.
    Chahin N, Engel AG. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology. 2008;70(6):418–24.PubMedCrossRefGoogle Scholar
  21. 21.
    Van der Meulen MF, Hoogendijk JE, Moons KG, Veldman H, Badrising UA, Wokke JH. Rimmed vacuoles and the added value of SMI-31 staining in diagnosing sporadic inclusion body myositis. Neuromuscul Disord. 2001;11:447–51.PubMedCrossRefGoogle Scholar
  22. 22.
    Greenberg SA, Pinkus GS, Amato AA, Pinkus JL. Myeloid dendritic cells in inclusion-body myositis and polymyositis. Muscle Nerve. 2007;35(1):17–23.PubMedCrossRefGoogle Scholar
  23. 23.
    Greenberg SA. Inclusion body myositis. Curr Opin Rheumatol. 2011;23(6):574–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Greenberg SA, Sanoudou D, Haslett JN, et al. Molecular profiles of inflammatory myopathies. Neurology. 2002;59(8):1170–82.PubMedCrossRefGoogle Scholar
  25. 25.
    Greenberg SA, Bradshaw EM, Pinkus JL, et al. Plasma cells in muscle in inclusion body myositis and polymyositis. Neurology. 2005;65(11):1782–7.PubMedCrossRefGoogle Scholar
  26. 26.
    • Salajegheh M, Lam T, Greenberg SA. Autoantibodies against a 43 kDa muscle protein in inclusion body myositis. PLoS One. 2011;6:e20266. Since microarray studies reported abundant immunoglobulin gene transcripts in IBM muscle derived from local abundant plasma cells, this provided a rationale for searching for circulating autoantibodies. Imunoblots against normal human muscle demonstrate that 52 % of IBM patient samples recognized a 43 kDa muscle protein. None of those with other diseases or healthy volunteers had this protein.PubMedCrossRefGoogle Scholar
  27. 27.
    Askanas V, Engel WK. Inclusion-body myositis: a myodegenerative conformational disorder associated with Abeta, protein misfolding, and proteasome inhibition. Neurology. 2006;66(2 Suppl 1):S39–48.PubMedCrossRefGoogle Scholar
  28. 28.
    Wojcik S, Engel WK, McFerrin J, Paciello O, Askanas V. AbetaPP-overexpression and proteasome inhibition increase alpha B-crystallin in cultured human muscle: relevance to inclusion-body myositis. Neuromuscul Disord. 2006;16(12):839–44.PubMedCrossRefGoogle Scholar
  29. 29.
    Askanas V, Engel WK. Sporadic inclusion-body myositis: conformational multifactorial ageing-related degenerative muscle disease associated with proteasomal and lysosomal inhibition, endoplasmic reticulum stress, and accumulation of amyloid-β42 oligomers and phosphorylated tau. Presse Med. 2011;40(4 Pt 2):e219–35.PubMedCrossRefGoogle Scholar
  30. 30.
    Salajegheh M, Pinkus JL, Nazareno R, et al. Nature of “Tau” immunoreactivity in normal myonuclei and inclusion body myositis. Muscle Nerve. 2009;40(4):520–8.PubMedCrossRefGoogle Scholar
  31. 31.
    • Nogalska A, D’Agostino C, Engel WK, Klein WL, Askanas V. Novel demonstration of amyloid-β oligomers in sporadic inclusion-body myositis muscle fibers. Acta Neuropathol. 2010;120(5):661–6. Askanas’ group reported for the first time in 2010 that IBM muscle samples had accumulation of toxic low-molecular weight amyloid β oligomers on dot-immunoblots with a variety of molecular weights and intensity but none of the control muscle biopsies had amyloid β oligomers. Nonfibrillar cytotoxic “Aβ-Derived Diffusible Ligands” originally derived from Aβ42 are prominently increased on dot-immunoblots, being consistent with the concept that intracellular toxicity of Ab42 oligomers is likely an important aspect of IBM pathogenesis. Finally, they demonstrated in cultured human muscle fibers that inhibition of autophagy is a novel cause of Aβ oligomerization.PubMedCrossRefGoogle Scholar
  32. 32.
    Salajegheh M, Pinkus JL, Taylor JP, et al. Sarcoplasmic redistribution of nuclear TDP-43 in inclusion body myositis. Muscle Nerve. 2009;40:19–31.PubMedCrossRefGoogle Scholar
  33. 33.
    Verma A, Bradley WG, Ringel SP. Treatment-responsive polymyositis transforming into inclusion body myositis. Neurology. 2008;P060.19.Google Scholar
  34. 34.
    Benveniste O, Guiguet M, Freebody J, et al. Long-term observational study of sporadic inclusion body myositis. Brain. 2011;134(Pt 11):3176–84.PubMedCrossRefGoogle Scholar
  35. 35.
    Amato AA, Barohn RJ, Jackson CE, Pappert EJ, Sahenk Z, Kissel JT. Inclusion body myositis: treatment with intravenous immunoglobulin. Neurology. 1994;44(8):1516–8.PubMedCrossRefGoogle Scholar
  36. 36.
    Dalakas MC, Sonies B, Dambrosia J, Sekul E, Cupler E, Sivakumar K. Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study. Neurology. 1997;48:712–6.PubMedCrossRefGoogle Scholar
  37. 37.
    Dalakas MC, Koffman B, Fujii M, Spector S, Sivakumar K, Cupler E. A controlled study of intravenous immunoglobulin combined with prednisone in the treatment of IBM. Neurology. 2001;56:323–7.PubMedCrossRefGoogle Scholar
  38. 38.
    Muscle Study Group. Randomized pilot trial of betaINF1a (Avonex) in patients with inclusion body myositis. Neurology. 2001;57:1566–70.CrossRefGoogle Scholar
  39. 39.
    Muscle Study Group. Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis. Neurology. 2004;63:718–20.CrossRefGoogle Scholar
  40. 40.
    Badrising UA, Maat-Schieman ML, Ferrari, et al. Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo. Ann Neurol. 2002;51:369–72.PubMedCrossRefGoogle Scholar
  41. 41.
    Lindberg C, Trysberg E, Tarkowski A, Oldfors A. Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study. Neurology. 2003;61:260–2.PubMedCrossRefGoogle Scholar
  42. 42.
    Rutkove SB, Parker RA, Nardin RA, Connolly CE, Felic KJ, Raynor EM. A pilot randomized trial of oxandrolone in inclusion body myositis. Neurology. 2002;58(7):1081–7.PubMedCrossRefGoogle Scholar
  43. 43.
    Barohn RJ, Herbelin L, Kissel JT, et al. Pilot trial of etanercept in the treatment of inclusion-body myositis. Neurology. 2006;66(2 Suppl 1):S123–4.PubMedCrossRefGoogle Scholar
  44. 44.
    Dalakas MC, Rakocevic G, Schmidt J, et al. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain. 2009;132(Pt 6):1536–44.PubMedCrossRefGoogle Scholar
  45. 45.
    Sancricca C, Mora M, Ricci E, Tonali PA, Mantegazza R, Mirabella M. Pilot trial of simvastatin in the treatment of sporadic inclusion-body myositis. Neurol Sci. 2011;32(5):841–7.PubMedCrossRefGoogle Scholar
  46. 46.
    Saperstein DS, Levine T, Hank N, Kitazawa M, Bowser R, LaFerla F. Pilot Trial of lithium treatment in inclusion body myositis. Neurology. 2011;76 Suppl 4:A106.Google Scholar
  47. 47.
    Pasquali L, Longone P, Isidoro C, Ruggieri S, Paparelli A, Fornai F. Autophagy, lithium, and amyotrophic lateral sclerosis. Muscle Nerve. 2009;40(2):173–94.PubMedCrossRefGoogle Scholar
  48. 48.
    Wang Y, He J, McVey AL, et al. Twelve-month change of IBMFRS in the arimocolomol inclusion body myositis pilot study. Poster 7.255 presented at the American Academy of Neurology. Annual Meeting. New Orleans, LA, USA; April 26 2012. Actual page etc from Dr. Baroh’s CV).Google Scholar
  49. 49.
    Sekul EA, Dalakas MC. Inclusion body myositis: new concepts. Semin Neurol. 1993;13(3):256–63.PubMedCrossRefGoogle Scholar
  50. 50.
    Cox FM, Titulaer MJ, Sont JK, Wintzen AR, Verschuuren JJ, Badrising UA. A 12-year follow-up in sporadic inclusion body myositis: an end stage with major disabilities. Brain. 2011;134(Pt 11):3167–75.PubMedCrossRefGoogle Scholar
  51. 51.
    Arnardottir S, Alexanderson H, Lundberg IE, Borg K. Sporadic inclusion body myositis: pilot study on the effects of a home exercise program on muscle function, histopathology, and inflammatory reaction. J Rehabil Med. 2003;35(1):31–5.PubMedCrossRefGoogle Scholar
  52. 52.
    Johnson GL, et al. The effectiveness of an individualized, home-based functional exercise program for patients with sporadic inclusion body myositis. J Clin Neuromuscul Dis. 2007;8:187–94.CrossRefGoogle Scholar
  53. 53.
    Johnson LG, Collier KE, Edwards DJ, et al. Improvement in aerobic capacity after an exercise program in sporadic inclusion body myositis. J Clin Neuromuscul Dis. 2009;10(4):178–84.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  1. 1.Department of NeurologyUniversity of Kansas Medical CenterKansas CityUSA

Personalised recommendations